Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1998

View Archived Issues

Possible therapeutic strategy for atherosclerosis: interruption of CD40 signaling

Platelet activity after coronary thrombolysis with reteplase and alteplase

SQ-29548 protects against COX inhibitor-associated postischemic cardiac dysfunction

Novel antiasthmatic TYB-2285 reported to inhibit late asthmatic response and histamine release

Rights to rhFIX gene for use in gene therapy available from BTG

Wyeth-Ayerst to market Abelcet in Greece

Ergo Science completes enrollment of phase II Ergoset clinical study for obesity

Texas Biotechnology reports additional positive phase IIa trial results for TBC-11251

Inhibitor of IgE antibody production discovered by Asahi Chemical

Aronex expands clinical development program for Atragen

Gelatinase inhibitors in development by Kotobuki

Bronchodilators with a pyrrolopyrazolopyrimidine structure patented by Pola

Novavax extends option agreement with Cantab

Dainippon claims series with potential for urinary incontinence

Protein farnesyltransferase inhibitors from Kyowa Hakko

Roche: Q2 1998 highlights

Potassium channel-blocking immunosuppressants from Merck & Co.

KRH-594: profile of a new angiotensin II receptor antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.